FSP1 , a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers

Nsengiyumva Emmanuel; Hongen Li; Jing Chen; Yilei Zhang

doi:10.18632/oncotarget.28301

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Perspectives:

FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers

Nsengiyumva Emmanuel, Hongen Li, Jing Chen and Yilei Zhang _

PDF | Full Text | How to cite

Oncotarget. 2022; 13:1136-1139. https://doi.org/10.18632/oncotarget.28301

Metrics: PDF 1472 views | Full Text 2329 views | ?

Abstract

Nsengiyumva Emmanuel1^,*, Hongen Li2^,*, Jing Chen3 and Yilei Zhang1^,4

1 The Institute of Molecular and Translational Medicine, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xi’an Jiaotong University, Xi’an 710049, China

2 Department of Thoracic Surgery, Ruyang People’s Hospital, Luoyang 471200, China

3 Shaanxi Stem Cell Application Engineering Research Center, Shaanxi Jiuzhou Biomedical Science and Technology Group, Xi’an 710065, China

4 Department of Thoracic Surgery, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an 710061, China

* These authors contributed equally to this work

Correspondence to:

Yilei Zhang,

email:

[email protected]

Keywords: KEAP1/NRF2; lung cancer; ferroptosis; radioresistance; therapy

Received: September 05, 2022 Accepted: October 12, 2022 Published: October 19, 2022

Copyright: © 2022 Emmanuel et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

In the study of "A targetable CoQ-FSP1 axis drives ferroptosis- and radiation-resistance in KEAP1 inactive lung cancers" which was published earlier in Nature Communications, the authors have identified a novel KEAP1/NRF2 target gene, FSP1, and demonstrated that FSP1 plays an essential role in NRF2-mediated ferroptosis resistance and radioresistance in KEAP1-deficient lung cancer cells. Currently, many NRF2 target genes have been found to participate in the regulation of ferroptosis, and exactly which one plays a dominant role seems unclear. This study proposes that FSP1 is the key effector in NRF2-mediated ferroptosis resistance and radioresistance in KEAP-deficient lung cancer cells, as we discussed in the manuscript.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28301

Publication Alerts

Research Perspectives:

FSP1, a novel KEAP1/NRF2 target gene regulating ferroptosis and radioresistance in lung cancers

Abstract